Sökning: onr:"swepub:oai:DiVA.org:uu-220791" >
Plasma YKL-40 in Pa...
Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab : RESULTS from the NORDIC VII Study
-
Tarpgaard, Line S. (författare)
-
Guren, Tormod K. (författare)
-
- Glimelius, Bengt (författare)
- Uppsala universitet,Institutionen för radiologi, onkologi och strålningsvetenskap
-
visa fler...
-
Christensen, Ib J. (författare)
-
Pfeiffer, Per (författare)
-
Kure, Elin H. (författare)
-
Sorbye, Halfdan (författare)
-
Ikdahl, Tone (författare)
-
Yilmaz, Mette (författare)
-
Johansen, Julia S. (författare)
-
Tveit, Kjell Magne (författare)
-
visa färre...
-
(creator_code:org_t)
- 2014-02-03
- 2014
- Engelska.
-
Ingår i: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 9:2, s. e87746-
- Relaterad länk:
-
https://uu.diva-port... (primary) (Raw object)
-
visa fler...
-
https://journals.plo...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: We aim to test the hypothesis that high plasma YKL-40 is associated with short progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with first-line oxaliplatin and 5-flourouracil with or without cetuximab. Patients and Methods: A total of 566 patients in the NORDIC VII Study were randomized 1:1:1 to arm A (Nordic FLOX), arm B (Nordic FLOX + cetuximab), or arm C (Nordic FLOX + cetuximab for 16 weeks followed by cetuximab alone as maintenance therapy). Pretreatment plasma samples were available from 510 patients. Plasma YKL-40 was determined by ELISA and dichotomized according to the age-corrected 95% YKL-40 level in 3130 healthy subjects. Results: Pretreatment plasma YKL-40 was elevated in 204 patients (40%), and median YKL-40 was higher in patients with mCRC than in healthy subjects (age adjusted, P < 0.001). Patients with elevated YKL-40 had shorter PFS than patients with normal YKL-40 (7.5 vs. 8.2 months; hazard ratio (HR) = 1.27 95% confidence interval (CI) 1.05-1.53 P = 0.013) and shorter OS (16.8 vs. 23.9 months; HR = 1.33, 1.04-1.69, P = 0.024). Multivariate Cox analysis demonstrated that elevated pretreatment YKL-40 was an independent biomarker of short OS (HR = 1.12, 1.01-1.25, P = 0.033). The ratio of the updated plasma YKL-40 (i.e. level after 1, 2, 8 weeks of treatment, and at end of treatment compared to the baseline level) was associated with OS (HR = 1.27, 1.06-1.52, P = 0.011). Conclusions: Plasma YKL-40 is an independent prognostic biomarker in patients with mCRC treated with first-line oxaliplatin-based therapy alone or combined with cetuximab.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
PLOS ONE
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Tarpgaard, Line ...
-
Guren, Tormod K.
-
Glimelius, Bengt
-
Christensen, Ib ...
-
Pfeiffer, Per
-
Kure, Elin H.
-
visa fler...
-
Sorbye, Halfdan
-
Ikdahl, Tone
-
Yilmaz, Mette
-
Johansen, Julia ...
-
Tveit, Kjell Mag ...
-
visa färre...
- Artiklar i publikationen
-
PLOS ONE
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet